Clodronate liposome (Cl-LPM) pre-treatment in male CD1 mice before controlled cortical impact (CCI) reduced lesion volume at 1 and 3 days post-injury, attenuated Evans blue/IgG BBB leakage, and improved cortical blood flow by laser speckle imaging (n = 5β8/group) . Flow cytometry quantified morphological shifts of circulating CD115+/Ly6Chi monocytes: FSC-A rose from ~104,000β107,000 (sham) to ~111,000 (control CCI) and ~115,000 (Cl-LPM CCI), while SSC-A granularity rose from 27,114 Β± 746 (control CCI) to 34,132 Β± 1885 (Cl-LPM CCI). Cytology confirmed cell size increases from 34.9 Β΅mΒ³ (naΓ―ve) to 43.7 Β΅mΒ³ (CCI) to 67.4 Β΅mΒ³ (Cl-LPM CCI) .
scRNA-seq of enriched blood monocytes (4,663 control vs 4,201 Cl-LPM cells; ~7,055 reads/cell) resolved 11 clusters, with Cl-LPM dominated by classical Ccr2hi/Ccr2lo, a Chil3/Ym1-Apoe immunoregulatory non-classical subtype (C4), and a neutrophil-like cluster (C9) marked by Elane, Prtn3, Mpo, Ctsg, and proliferative genes (Mki67, Hmgb2) with oxidative phosphorylation as the top GO/IPA pathway . Pseudotime suggested C9 differentiates from classical monocytes. Transfer of 150k Cl-LPM-derived peripheral monocytes reduced recipient lesion volume at 1 dpi, supporting a direct effector role. Independent literature corroborates that Gfi1 promotes the neutrophil program by repressing c-Fos/Egr-1 and dampening ERK1/2 , and that IRF8 acts in committed progenitors to favor monocyte over neutrophil output β context that plausibly explains the Gfi1-high/Nr4a1-low signature seen here, though the paper does not test these factors directly.
Confidence: moderate. The descriptive morphology/flow data are solid and internally consistent, but the causal OXPHOS β resolution narrative is inferred from pathway enrichment, not measured energetics (no Seahorse, no ex vivo functional assays), and HARKing risk applies to the emergency-monopoiesis framing built after observing Cl-LPM effects.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.